Moderna (MRNA) Stock: Melanoma Vaccine Data Pushes Shares to 52-Week High

TLDR

• Moderna stock jumped 16% on Wednesday, reaching a new 52-week high of $50 after positive cancer vaccine trial results
• Five-year melanoma vaccine data showed 49% reduction in recurrence or death when combined with Merck’s Keytruda
• The company is shifting from COVID-only business to diversified biotech with multiple revenue streams including respiratory vaccines
• Wall Street maintains Hold rating with average price target of $29.93, suggesting 39.91% downside from current levels
• Moderna and Merck are testing the personalized cancer vaccine technology for lung, kidney, and bladder cancers

Moderna stock climbed roughly 16% during Wednesday’s trading session. The shares reached $50, marking a new 52-week high for the biotech company.

Moderna, Inc., MRNA

The rally followed the release of five-year follow-up data from a melanoma vaccine trial. Moderna partnered with Merck on the experimental treatment.

The phase 2 study examined patients with high-risk melanoma who had surgery. Results showed the investigational therapy reduced recurrence or death risk by 49% when combined with Merck’s Keytruda.

The vaccine alone did not achieve these results. Patients received the combination therapy for better outcomes.

The experimental treatment goes by the name intismeran autogene. It uses messenger RNA technology to trigger an immune response.

The therapy is personalized for each patient. It targets unique mutations found in individual tumors.

Revenue Diversification Takes Shape

Moderna is moving beyond its COVID vaccine business model. The company now has multiple revenue streams in development.

The melanoma vaccine with Merck stands as the biggest long-term growth driver. Investors are watching for Phase 3 progress and expansion into additional cancer types.

Moderna is building a respiratory vaccine portfolio. This includes flu, RSV, and combination shots that could provide recurring annual revenue.

The company is cutting costs and improving manufacturing efficiency. These moves bring Moderna closer to breakeven.

New government contracts and global distribution deals provide additional revenue support. The cancer vaccine partnerships add to this foundation.

Competition and Price Targets

Moderna faces direct competition from major pharmaceutical companies. Pfizer, BioNTech, GSK, and Sanofi are all investing heavily in respiratory and oncology vaccines.

Revenue is not expected to return to pandemic-era levels anytime soon. The company peaked during the COVID vaccine rollout.

Wall Street analysts give Moderna a Hold consensus rating. This breaks down to one Buy, 15 Hold, and four Sell recommendations.

The average price target sits at $29.93. This suggests 39.91% downside from current trading levels.

Expanding Cancer Treatment Pipeline

Moderna and Merck are running additional clinical trials beyond melanoma. The companies are testing their targeted technology on several tumor types.

Lung cancer trials are underway using the personalized vaccine approach. Kidney cancer patients are also enrolled in studies.

Bladder cancer represents another testing ground for the therapy. These trials will determine if the technology works across different cancer types.

The five-year follow-up data came from patients who underwent surgery for high-risk melanoma. The extended timeframe provides insight into the treatment’s durability.

The post Moderna (MRNA) Stock: Melanoma Vaccine Data Pushes Shares to 52-Week High appeared first on CoinCentral.